CA2436076A1 - Methodes et compositions permettant de stimuler l'angiogenese - Google Patents

Methodes et compositions permettant de stimuler l'angiogenese Download PDF

Info

Publication number
CA2436076A1
CA2436076A1 CA002436076A CA2436076A CA2436076A1 CA 2436076 A1 CA2436076 A1 CA 2436076A1 CA 002436076 A CA002436076 A CA 002436076A CA 2436076 A CA2436076 A CA 2436076A CA 2436076 A1 CA2436076 A1 CA 2436076A1
Authority
CA
Canada
Prior art keywords
pdgf
vegf
fgf
angiogenesis
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002436076A
Other languages
English (en)
Inventor
Robert Pawliuk
Philippe Leboulch
Yihai Cao
Renhai Cao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bluebird Bio Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2436076A1 publication Critical patent/CA2436076A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne des méthodes permettant de stimuler l'angiogenèse par l'administration de facteurs angiogéniques. Ces facteurs peuvent être administrés sous forme de gradient dans une zone de tissu localisée afin de diriger la croissance vasculaire.
CA002436076A 2001-01-26 2002-01-18 Methodes et compositions permettant de stimuler l'angiogenese Abandoned CA2436076A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26445701P 2001-01-26 2001-01-26
US60/264,457 2001-01-26
PCT/US2002/001666 WO2002058718A2 (fr) 2001-01-26 2002-01-18 Methodes et compositions permettant de stimuler l'angiogenese

Publications (1)

Publication Number Publication Date
CA2436076A1 true CA2436076A1 (fr) 2002-08-01

Family

ID=23006154

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002436076A Abandoned CA2436076A1 (fr) 2001-01-26 2002-01-18 Methodes et compositions permettant de stimuler l'angiogenese

Country Status (5)

Country Link
EP (1) EP1355659A2 (fr)
JP (1) JP4434584B2 (fr)
AU (1) AU2002247007B2 (fr)
CA (1) CA2436076A1 (fr)
WO (1) WO2002058718A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
JP2005168654A (ja) * 2003-12-09 2005-06-30 Kissei Pharmaceut Co Ltd 増殖因子結合低分子ヘパリン修飾体
FR2891149B1 (fr) * 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
EP1948210A4 (fr) * 2005-11-08 2010-07-14 Found Biomedical Res & Innov Methode de traitement d'une maladie cardiaque ischemique
FR2914191A1 (fr) * 2007-03-29 2008-10-03 Proteins & Peptides Man Composition angiogenique.
RU2498820C2 (ru) 2008-09-26 2013-11-20 Адосиа Комплекс, образованный полисахаридом и нвр
US20120141424A1 (en) * 2009-01-07 2012-06-07 Vegenics Pty Limited Materials and Methods for the Treatment of Hypertension
GB201504665D0 (en) * 2015-03-19 2015-05-06 Cell Therapy Ltd Composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889919A (en) * 1986-08-13 1989-12-26 Zymogenetics, Inc. Biologically active PDGF derived A-chain homodimers
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
NZ237832A (en) * 1990-04-17 1994-05-26 Curative Tech Inc Coating a prosthetic surface with mammalian cells
AU6778794A (en) * 1993-04-29 1994-11-21 Washington University Use of platelet-derived growth factor to improve collateral circulation
WO2000041732A1 (fr) * 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Compositions hydrogel pour l'administration controlee de vecteurs viraux, et leurs procedes d'utilisation

Also Published As

Publication number Publication date
AU2002247007B2 (en) 2006-12-07
WO2002058718A2 (fr) 2002-08-01
EP1355659A2 (fr) 2003-10-29
JP4434584B2 (ja) 2010-03-17
WO2002058718A3 (fr) 2003-04-17
JP2005506279A (ja) 2005-03-03

Similar Documents

Publication Publication Date Title
AU2001268149B2 (en) Methods and compounds for controlled release of recombinant parvovirus vectors
JP4859317B2 (ja) 薬剤放出生分解性繊維インプラント
US20030139333A1 (en) Methods and compositions for promoting angiogenesis
JP4485124B2 (ja) 電気処理されたコラーゲン
US20080031923A1 (en) Biologic Replacement for Fibrin Clot
CA2433936A1 (fr) Procede d'injection myocardiale localisee dans le traitement du myocarde ischemique
EA001616B1 (ru) Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
WO2004030706A2 (fr) Implants bioactifs
CN1198675A (zh) 含有hgf基因的药物
US20080102059A1 (en) Treatment for arthritis
AU2002247007B2 (en) Use of compositions containing PDGF-BB for promoting angiogenesis
AU772857B2 (en) Method of inducing angiogenesis
AU2002247007A1 (en) Use of compositions containing PDGF-BB for promoting angiogenesis
WO1989007944A1 (fr) Procede et dispositif de neovascularisation a localisation controlee
CN103638002A (zh) 包囊的肝细胞组合物
EA019099B1 (ru) Способ направленной доставки трансгена в миокард пациента с ишемией миокарда
CN1630538A (zh) 用vegf－b刺激血管生成
US20020013261A1 (en) Methods and compositions for promoting angiogenesis using polyethylene glycol (PEG) polymers
Vranckx et al. 15 Gene Transfer of Growth Factors for Wound Repair
WO2007059303A2 (fr) Compositions pour l'expression coordonnee de vegf et de pdgf, et methodes d'utilisation
Davidson 13 Gene Therapy of Wounds
EP1773373A2 (fr) Procede de modulation, de regulation et/ou de stabilisation de l'angiogenese
EP0968724A1 (fr) Utilisation des vecteurs virales pour le traitement du système nerveux périphérique et central blessé
Wnek et al. Gene-Activated Matrix/Neil Davies
Aslan et al. 184. Nonvirally Electrotransfected Human Mesenchymal Stem Cells: A Novel Platform for Bone Gene Therapy Based on Autocrine and Paracrine Mechanisms

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued